Section Review: Cardiovascular & Renal: Glycoprotein IIb/IIIa antagonists

Glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists have been shown to be effective in reducing the rate of ischaemic complications due to pathophysiological conditions such as atherosclerosis or coronary intervention. This review will cover all patenting activity in this now mature field of research up to and including August 1996, and will focus on the more significant patents and patent applications.